Financials in USD. Standardized financial statements.
A compact view of how Acorda Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $117.63M | $118.57M | $129.07M | $152.97M | $192.41M | $471.43M | $588.29M | $519.60M | $492.66M | $401.48M |
| Revenue Growth? | -0.8% | -8.1% | -15.6% | -20.5% | -59.2% | -19.9% | +13.2% | +5.5% | +22.7% | 0.0% |
| Cost of Revenue? | $46.05M | $30.33M | $40.79M | $33.51M | $34.85M | $99.31M | $135.71M | $108.11M | $92.93M | $80.61M |
| Gross Profit? | $71.59M | $88.23M | $88.28M | $119.45M | $157.56M | $372.12M | $452.57M | $411.49M | $399.73M | $320.87M |
| Gross Margin? | +60.9% | +74.4% | +68.4% | +78.1% | +81.9% | +78.9% | +76.9% | +79.2% | +81.1% | +79.9% |
| Operating Expenses? | $94.85M | $130.27M | $165.58M | $206.35M | $278.56M | $278.64M | $347.40M | $421.32M | $354.84M | $275.28M |
| Operating Income? | -$23.26M | -$42.04M | -$77.30M | -$86.90M | $14.55M | $38.49M | -$232.81M | -$35.98M | $33.99M | $36.39M |
| EBITDA? | -$201.82M | -$10.03M | -$44.80M | -$64.95M | $40.18M | $148.49M | $443.15M | $16.32M | $55.79M | $54.77M |
| Income Before Tax | -$296.02M | -$35.25M | -$109.07M | -$107.67M | -$274.25M | $20.42M | -$251.88M | -$42.27M | $19.37M | $28.01M |
| Income Tax Expense | -$43.17M | $30.67M | -$5.12M | -$8.07M | -$1.28M | -$13.26M | -$28.53M | -$6.67M | $8.31M | $10.34M |
| Net Income? | -$252.85M | -$65.92M | -$103.95M | -$99.59M | -$272.96M | $33.68M | -$223.36M | -$34.62M | $11.06M | $17.67M |
| EPS? | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 | $85.98 | $-582.69 | $-91.79 | $31.42 | $51.53 |
| Diluted EPS? | $-203.59 | $-66.90 | $-195.75 | $-246.40 | $-689.42 | $85.38 | $-583.20 | $-91.79 | $30.00 | $50.40 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality